Table 3.
Clinical and demographic characteristics of participants stratified by region of enrollment (n = 7061)
| Region of enrollment | ||
|---|---|---|
| North America (n = 6318) | Non-North America (n = 743) | |
| n (%) | n (%) | |
| Regimen | ||
| 3HP-DOT (n = 3643)* | 3254 (51.5) | 389 (52.4) |
| 9H-SAT (n = 3418)* | 3064 (48.5) | 354 (47.6) |
| Age, years (median = 37) | ||
| <37 (n = 3413) | 3048 (48.2) | 365 (49.1) |
| ⩾37 (n = 3648) | 3270 (51.8) | 378 (50.9) |
| Sex | ||
| Female (n = 3194) | 2838 (44.9) | 356 (47.9) |
| Male (n = 3867) | 3480 (55.1) | 387 (52.1) |
| Race | ||
| African (n = 1642) | 1642 (26) | — |
| Asian (n = 888) | 888 (14.1) | — |
| Other (n = 1001) | 258 (4.1) | 743 (100) |
| White (n = 3530) | 3530 (55.9) | — |
| Ethnicity | ||
| Hispanic (n = 2650) | 2650 (41.9) | — |
| Non-Hispanic (n = 3668) | 3668 (58.1) | — |
| Spain (n = 248) | — | 248 (33.4) |
| Brazil (n = 495) | — | 495 (66.6) |
| Country of birth | ||
| US (n = 2519) | 2519 (39.9) | — |
| Non-US (n = 4542) | 3799 (60.1) | 743 (100) |
| HIV status | ||
| Negative (n = 3509) | 3142 (49.7) | 367 (49.4) |
| Positive (n = 206) | 148 (2.3 | 58 (7.8) |
| Unknown (n = 3346) | 3028 (47.9) | 318 (42.8) |
| Body mass index, kg/m2 | ||
| <18.5 (n = 131) | 108 (1.7) | 23 (3.1) |
| 18.5–24.9 (n = 2146) | 1813 (28.7) | 333 (44.8) |
| 25–29.9 (n = 2503) | 2258 (35.7) | 245 (33) |
| ⩾30 (n = 2281) | 2139 (33.9 | 142 (19.1) |
| Educational level | ||
| ⩽8th grade (n = 1444) | 1145 (18.1) | 299 (40.2) |
| 9th grade, some college (n = 4384) | 3997 (63.3) | 387 (52.1) |
| College or higher (n = 1233) | 1176 (18.6) | 57 (7.7) |
| History of incarceration | ||
| No (n = 6665) | 5925 (93.8) | 740 (99.6) |
| Yes (n = 396) | 393 (6.2) | 3 (0.4) |
| Unemployment | ||
| No (n = 6252) | 5534 (87.6) | 718 (96.6) |
| Yes (n = 809) | 784 (12.4) | 25 (3.4) |
| Homelessness | ||
| No (n = 6553) | 5815 (92.0) | 738 (99.3) |
| Yes (n = 508) | 503 (8.0) | 5 (0.7) |
| Alcohol consumption | ||
| Use (n = 3229) | 2925 (46.3) | 304 (40.9) |
| Abuse (n = 526) | 484 (7.7) | 42 (5.7) |
| No (n = 3306) | 2909 (46.0) | 397 (53.4) |
| Injection drug use ever | ||
| No (n = 6780) | 6052 (95.8) | 728 (98.0) |
| Yes (n = 281) | 266 (4.2) | 15 (2.0) |
| Chronic liver disease | ||
| No (n = 6787) | 6068 (96.0) | 719 (96.8) |
| Yes (n = 274) | 250 (4.0) | 24 (3.2) |
| Current smoker | ||
| No (n = 4941) | 4394 (69.5) | 547 (73.6) |
| Yes (n = 2120) | 1924 (30.5) | 196 (26.4) |
| Potential for pregnancy | ||
| Female (n = 2506) | 2243 (35.5) | 263 (35.4) |
| Pregnancy (n = 108) | 105 (1.7) | 3 (0.4) |
| Not possible (n = 4447) | 3970 (62.8) | 477 (64.2) |
| Methadone use | ||
| No (n = 6920) | 6182 (97.8) | 738 (99.3) |
| Yes (n = 141) | 136 (2.2) | 5 (0.7) |
| Concomitant medications ⩾4 | ||
| No (n = 6069) | 5367 (84.9) | 702 (94.5) |
| Yes (n = 992) | 951 (15.1) | 41 (5.5) |
| Contact TB | ||
| No (n = 2198) | 2114(33.5) | 84(11.3) |
| Yes (n = 4863) | 4204 (66.5) | 659 (88.7) |
| TST conversion | ||
| No (n = 4749) | 4074 (64.5) | 675 (90.8) |
| Yes (n = 2312) | 2244 (35.5) | 68 (9.2) |
| Fibrosis | ||
| No (n = 6873) | 6133 (97.1) | 740 (99.6) |
| Yes (n = 188) | 185 (2.9) | 3 (0.4) |
| HIV/LTBI treatment | ||
| No (n = 6865) | 6178 (97.8) | 687 (92.5) |
| Yes (n = 196) | 140 (2.2) | 56 (7.5) |
*
3HP-DOT = 3 months of directly observed once-weekly RPT (maximum dose, 900 mg) plus INH (maximum dose, 900 mg); 9H-SAT = 9 months of daily selfadministered INH (maximum dose, 300 mg).
H, INH = isoniazid; P, RPT=rifapentine; DOT = directly observed therapy; SAT = self-administered treatment; HIV = human immunodeficiency virus; LTBI = latent tuberculous infection.